{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T02:11:54Z","timestamp":1770171114820,"version":"3.49.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["F31CA284655"],"award-info":[{"award-number":["F31CA284655"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P20GM125503"],"award-info":[{"award-number":["P20GM125503"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["KL2TR003108"],"award-info":[{"award-number":["KL2TR003108"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R37CA251763"],"award-info":[{"award-number":["R37CA251763"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite significant therapeutic advances, multiple myeloma (MM) remains incurable in most patients due to frequent tumor relapse. A major contributor to relapse is clonal heterogeneity, where subclones exhibit distinct mechanisms of therapy resistance, along with the presence of drug-resistant dormant cells. Eliminating these distinct populations, which often coexist in the tumor niche, is clinically challenging. Identifying survival mechanisms shared by drug-resistant proliferating and dormant cells holds potential for the simultaneous elimination of different tumor-repopulating clones.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To identify shared mechanisms of therapeutic resistance, we analyzed clinical databases and drug-resistant myeloma cell lines. We employed pharmacologic approaches to target common candidates identified in our analysis and assessed their impact on tumor progression and survival in preclinical mouse models containing both therapy-resistant and dormant cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified upregulation of several components of the Notch signaling pathway in both dormant and drug-resistant MM cells, which correlated with poor clinical outcomes in newly diagnosed MM patients. Selective blockade of NOTCH3 with a neutralizing antibody or pan-Notch inhibition with a bone-targeted inhibitor reduced tumor burden and eliminated coexisting dormant and bortezomib-resistant cells in clinically relevant models of MM disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings reveal that NOTCH3-dependent survival programs represent a shared vulnerability in both cells refractory to therapy and dormant cells. These programs can be exploited to overcome the diverse mechanisms by which cancer cells evade therapy, potentially preventing disease relapse and extending remission in patients with MM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-025-03630-1","type":"journal-article","created":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T23:37:12Z","timestamp":1767569832000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells"],"prefix":"10.1186","volume":"45","author":[{"given":"Hayley M.","family":"Sabol","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bethany C.","family":"Paxton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aric","family":"Anloague","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Japneet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mattie R.","family":"Nester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharmin","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter I.","family":"Croucher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle M.","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corey O.","family":"Montgomery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey B.","family":"Stambough","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Lowry","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Ambrogini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank H.","family":"Ebetino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Schinke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cody","family":"Ashby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2083-2774","authenticated-orcid":false,"given":"Jes\u00fas","family":"Delgado-Calle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"issue":"10272","key":"3630_CR1","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"N van de Donk","year":"2021","unstructured":"van de Donk N, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397(10272):410\u201327.","journal-title":"Lancet"},{"issue":"19","key":"3630_CR2","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1182\/blood.2020008734","volume":"139","author":"E Kastritis","year":"2022","unstructured":"Kastritis E, Terpos E, Dimopoulos MA. How I treat relapsed multiple myeloma. Blood. 2022;139(19):2904\u201317.","journal-title":"Blood"},{"key":"3630_CR3","doi-asserted-by":"crossref","unstructured":"Li S, Liu J, Peyton M, Lazaro O, McCabe SD, Huang X, et al. Multiple myeloma insights from Single-Cell analysis: clonal Evolution, the Microenvironment, therapy Evasion, and clinical implications. Cancers (Basel). 2025;17(4):653.","DOI":"10.3390\/cancers17040653"},{"key":"3630_CR4","doi-asserted-by":"publisher","first-page":"973836","DOI":"10.3389\/fonc.2022.973836","volume":"12","author":"AG Solimando","year":"2022","unstructured":"Solimando AG, Malerba E, Leone P, Prete M, Terragna C, Cavo M, et al. Drug resistance in multiple myeloma: soldiers and weapons in the bone marrow niche. Front Oncol. 2022;12:973836.","journal-title":"Front Oncol"},{"issue":"12","key":"3630_CR5","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.18632\/oncotarget.1497","volume":"4","author":"J Abdi","year":"2013","unstructured":"Abdi J, Chen G, Chang H. Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. Oncotarget. 2013;4(12):2186\u2013207.","journal-title":"Oncotarget"},{"key":"3630_CR6","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ctrv.2018.09.001","volume":"70","author":"P Robak","year":"2018","unstructured":"Robak P, Drozdz I, Szemraj J, Robak T. Drug resistance in multiple myeloma. Cancer Treat Rev. 2018;70:199\u2013208.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"3630_CR7","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/blood.2018880930","volume":"134","author":"WH Khoo","year":"2019","unstructured":"Khoo WH, Ledergor G, Weiner A, Roden DL, Terry RL, McDonald MM, et al. A niche-dependent myeloid transcriptome signature defines dormant myeloma cells. Blood. 2019;134(1):30\u201343.","journal-title":"Blood"},{"key":"3630_CR8","doi-asserted-by":"publisher","first-page":"8983","DOI":"10.1038\/ncomms9983","volume":"6","author":"MA Lawson","year":"2015","unstructured":"Lawson MA, McDonald MM, Kovacic N, Hua Khoo W, Terry RL, Down J, et al. Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche. Nat Commun. 2015;6:8983.","journal-title":"Nat Commun"},{"issue":"1","key":"3630_CR9","doi-asserted-by":"publisher","first-page":"4517","DOI":"10.1038\/s41467-022-32145-y","volume":"13","author":"L Rasche","year":"2022","unstructured":"Rasche L, Schinke C, Maura F, Bauer MA, Ashby C, Deshpande S, et al. The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory States. Nat Commun. 2022;13(1):4517.","journal-title":"Nat Commun"},{"key":"3630_CR10","doi-asserted-by":"crossref","unstructured":"Sabol HM, Ashby C, Adhikari M, Anloague A, Kaur J, Khan S, et al. A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma. Haematologica. 2024;109(8):2606-18.","DOI":"10.3324\/haematol.2023.284443"},{"issue":"7","key":"3630_CR11","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.3324\/haematol.2019.221077","volume":"105","author":"M Colombo","year":"2020","unstructured":"Colombo M, Garavelli S, Mazzola M, Platonova N, Giannandrea D, Colella R, et al. Multiple myeloma exploits Jagged1 and Jagged2 to promote intrinsic and bone marrow-dependent drug resistance. Haematologica. 2020;105(7):1925\u201336.","journal-title":"Haematologica"},{"issue":"12","key":"3630_CR12","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/s41408-017-0001-3","volume":"7","author":"Y Muguruma","year":"2017","unstructured":"Muguruma Y, Yahata T, Warita T, Hozumi K, Nakamura Y, Suzuki R, et al. Jagged1-induced Notch activation contributes to the acquisition of bortezomib resistance in myeloma cells. Blood Cancer J. 2017;7(12):650.","journal-title":"Blood Cancer J"},{"issue":"4","key":"3630_CR13","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.bbrc.2015.10.076","volume":"467","author":"Y Ding","year":"2015","unstructured":"Ding Y, Shen Y. Notch increased vitronection adhesion protects myeloma cells from drug induced apoptosis. Biochem Biophys Res Commun. 2015;467(4):717\u201322.","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"3630_CR14","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.bbrc.2012.10.071","volume":"428","author":"D Xu","year":"2012","unstructured":"Xu D, Hu J, De Bruyne E, Menu E, Schots R, Vanderkerken K, et al. Dll1\/Notch activation contributes to bortezomib resistance by upregulating CYP1A1 in multiple myeloma. Biochem Biophys Res Commun. 2012;428(4):518\u201324.","journal-title":"Biochem Biophys Res Commun"},{"issue":"9","key":"3630_CR15","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1182\/blood-2003-07-2340","volume":"103","author":"Y Nefedova","year":"2004","unstructured":"Nefedova Y, Cheng P, Alsina M, Dalton WS, Gabrilovich DI. Involvement of Notch-1 signaling in bone marrow stroma-mediated de Novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood. 2004;103(9):3503\u201310.","journal-title":"Blood"},{"issue":"4","key":"3630_CR16","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1002\/jbmr.4496","volume":"37","author":"J Tao","year":"2022","unstructured":"Tao J, Srinivasan V, Yi X, Zhao Y, Zhang H, Lin X, et al. Bone-Targeted bortezomib inhibits bortezomib-Resistant multiple myeloma in mice by providing higher levels of bortezomib in bone. J Bone Min Res. 2022;37(4):629\u201342.","journal-title":"J Bone Min Res"},{"issue":"17","key":"3630_CR17","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1182\/blood-2014-03-564534","volume":"124","author":"S Chen","year":"2014","unstructured":"Chen S, Zhang Y, Zhou L, Leng Y, Lin H, Kmieciak M, et al. A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis. Blood. 2014;124(17):2687\u201397.","journal-title":"Blood"},{"issue":"19","key":"3630_CR18","doi-asserted-by":"publisher","first-page":"5102","DOI":"10.1158\/0008-5472.CAN-21-0524","volume":"81","author":"HM Sabol","year":"2021","unstructured":"Sabol HM, Ferrari AJ, Adhikari M, Amorim T, McAndrews K, Anderson J, et al. Targeting Notch inhibitors to the myeloma bone marrow niche decreases tumor growth and bone destruction without gut toxicity. Cancer Res. 2021;81(19):5102\u201314.","journal-title":"Cancer Res"},{"issue":"5","key":"3630_CR19","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/sj.thj.6200052","volume":"1","author":"K Asosingh","year":"2000","unstructured":"Asosingh K, Radl J, Van R, Van I, Vanderkerken CB. The 5TMM series: a useful in vivo mouse model of human multiple myeloma. Hematol J. 2000;1(5):351\u20136.","journal-title":"Hematol J"},{"issue":"6","key":"3630_CR20","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/S8756-3282(97)00056-2","volume":"20","author":"IR Garrett","year":"1997","unstructured":"Garrett IR, Dallas S, Radl J, Mundy GR. A murine model of human myeloma bone disease. Bone. 1997;20(6):515\u201320.","journal-title":"Bone"},{"issue":"3","key":"3630_CR21","first-page":"593","volume":"132","author":"J Radl","year":"1988","unstructured":"Radl J, Croese JW, Zurcher C, de MH VdE-V AM. Animal model of human disease. Multiple myeloma. Am J Pathol. 1988;132(3):593\u20137.","journal-title":"Am J Pathol"},{"key":"3630_CR22","doi-asserted-by":"crossref","unstructured":"Anloague A, Sabol HM, Kaur J, Khan S, Ashby C, Schinke C, et al. Novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myeloma. Haematologica. 2025;110(4):952\u201366.","DOI":"10.3324\/haematol.2024.286484"},{"issue":"23","key":"3630_CR23","doi-asserted-by":"publisher","first-page":"3936","DOI":"10.1158\/0008-5472.CAN-24-0857","volume":"84","author":"J Kaur","year":"2024","unstructured":"Kaur J, Adhikari M, Sabol HM, Anloague A, Khan S, Kurihara N, et al. Single-Cell transcriptomic analysis identifies senescent osteocytes that trigger bone destruction in breast cancer metastasis. Cancer Res. 2024;84(23):3936\u201352.","journal-title":"Cancer Res"},{"issue":"6","key":"3630_CR24","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","volume":"108","author":"F Zhan","year":"2006","unstructured":"Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, et al. The molecular classification of multiple myeloma. Blood. 2006;108(6):2020\u20138.","journal-title":"Blood"},{"key":"3630_CR25","doi-asserted-by":"publisher","first-page":"100785","DOI":"10.1016\/j.neo.2022.100785","volume":"28","author":"HM Sabol","year":"2022","unstructured":"Sabol HM, Amorim T, Ashby C, Halladay D, Anderson J, Cregor M, et al. Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction. Neoplasia. 2022;28:100785.","journal-title":"Neoplasia"},{"issue":"1","key":"3630_CR26","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s40164-025-00699-4","volume":"14","author":"HM Sabol","year":"2025","unstructured":"Sabol HM, Anloague A, Kaur J, Bustamante-Gomez C, Khan S, Paxton BC, et al. Healing of lytic lesions and restoration of bone health in multiple myeloma through sclerostin Inhibition. Exp Hematol Oncol. 2025;14(1):108.","journal-title":"Exp Hematol Oncol"},{"issue":"4","key":"3630_CR27","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1182\/blood-2007-07-102632","volume":"111","author":"Y Nefedova","year":"2008","unstructured":"Nefedova Y, Sullivan DM, Bolick SC, Dalton WS, Gabrilovich DI. Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy. Blood. 2008;111(4):2220\u20139.","journal-title":"Blood"},{"issue":"15","key":"3630_CR28","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1182\/blood-2015-08-665679","volume":"127","author":"B Paiva","year":"2016","unstructured":"Paiva B, Corchete LA, Vidriales MB, Puig N, Maiso P, Rodriguez I, et al. Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance. Blood. 2016;127(15):1896\u2013906.","journal-title":"Blood"},{"key":"3630_CR29","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.bone.2016.10.007","volume":"96","author":"J Delgado-Calle","year":"2017","unstructured":"Delgado-Calle J, Sato AY, Bellido T. Role and mechanism of action of sclerostin in bone. Bone. 2017;96:29\u201337.","journal-title":"Bone"},{"issue":"12","key":"3630_CR30","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1038\/leu.2017.152","volume":"31","author":"J Delgado-Calle","year":"2017","unstructured":"Delgado-Calle J, Anderson J, Cregor MD, Condon KW, Kuhstoss SA, Plotkin LI, et al. Genetic deletion of Sost or Pharmacological Inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth. Leukemia. 2017;31(12):2686\u201394.","journal-title":"Leukemia"},{"issue":"40","key":"3630_CR31","doi-asserted-by":"publisher","first-page":"68047","DOI":"10.18632\/oncotarget.19152","volume":"8","author":"RC Chai","year":"2017","unstructured":"Chai RC, McDonald MM, Terry RL, Kova\u010di\u0107 N, Down JM, Pettitt JA, et al. Melphalan modifies the bone microenvironment by enhancing osteoclast formation. Oncotarget. 2017;8(40):68047\u201358.","journal-title":"Oncotarget"},{"key":"3630_CR32","doi-asserted-by":"crossref","unstructured":"Bellido T, Delgado-Calle J. Ex vivo organ cultures as models to study bone biology. JBMR Plus. 2020;4(3):10.1002\/jbm4.10345.","DOI":"10.1002\/jbm4.10345"},{"issue":"6","key":"3630_CR33","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1172\/JCI74883","volume":"125","author":"DL Abravanel","year":"2015","unstructured":"Abravanel DL, Belka GK, Pan TC, Pant DK, Collins MA, Sterner CJ, et al. Notch promotes recurrence of dormant tumor cells following HER2\/neu-targeted therapy. J Clin Invest. 2015;125(6):2484\u201396.","journal-title":"J Clin Invest"},{"issue":"24","key":"3630_CR34","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa043445","volume":"352","author":"PG Richardson","year":"2005","unstructured":"Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352(24):2487\u201398.","journal-title":"N Engl J Med"},{"issue":"6","key":"3630_CR35","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1182\/blood-2008-07-167767","volume":"112","author":"S Kumar","year":"2008","unstructured":"Kumar S, Rajkumar SV. Many facets of bortezomib resistance\/susceptibility. Blood. 2008;112(6):2177\u20138.","journal-title":"Blood"},{"issue":"1","key":"3630_CR36","doi-asserted-by":"publisher","first-page":"54","DOI":"10.2174\/156802608783334015","volume":"8","author":"BP Imbimbo","year":"2008","unstructured":"Imbimbo BP. Therapeutic potential of gamma-secretase inhibitors and modulators. Curr Top Med Chem. 2008;8(1):54\u201361.","journal-title":"Curr Top Med Chem"},{"issue":"46","key":"3630_CR37","doi-asserted-by":"publisher","first-page":"46107","DOI":"10.1074\/jbc.M307757200","volume":"278","author":"GH Searfoss","year":"2003","unstructured":"Searfoss GH, Jordan WH, Calligaro DO, Galbreath EJ, Schirtzinger LM, Berridge BR, et al. Adipsin, a biomarker of Gastrointestinal toxicity mediated by a functional gamma-secretase inhibitor. J Biol Chem. 2003;278(46):46107\u201316.","journal-title":"J Biol Chem"},{"issue":"1","key":"3630_CR38","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s10637-019-00754-y","volume":"38","author":"LS Rosen","year":"2020","unstructured":"Rosen LS, Wesolowski R, Baffa R, Liao KH, Hua SY, Gibson BL, et al. A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody-drug conjugate, in patients with breast cancer and other advanced solid tumors. Invest New Drugs. 2020;38(1):120\u201330.","journal-title":"Invest New Drugs"},{"issue":"4","key":"3630_CR39","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1007\/s10637-018-0714-6","volume":"37","author":"DC Smith","year":"2019","unstructured":"Smith DC, Chugh R, Patnaik A, Papadopoulos KP, Wang M, Kapoun AM, et al. A phase 1 dose escalation and expansion study of tarextumab (OMP-59R5) in patients with solid tumors. Invest New Drugs. 2019;37(4):722\u201330.","journal-title":"Invest New Drugs"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03630-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03630-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03630-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T13:01:57Z","timestamp":1770123717000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-025-03630-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3630"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03630-1","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"assertion":[{"value":"26 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures involving animals were performed in accordance with guidelines issued by the University of Arkansas for Medical Sciences IACUC (protocol #2022200000489). Collection and de-identification of human bone samples for ex vivo studies were coordinated by the UAMS Winthrop P. Rockefeller Cancer Institute TBAPS and approved by the UAMS IRB (protocol # 262940). Deidentified primary CD138+ cells were obtained from MM patients during clinic visits at the University of Arkansas for Medical Sciences. Signed Institutional Review Board\u2013approved informed consent forms are kept on record at the University of Arkansas for Medical Sciences Tissue Biorepository and Procurement Service (TBAPS) under approved protocols IRB 262254 and 260887.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31"}}